Yatai Pharm: The cumulative deviation of the stock price increase over the past two days exceeds 20%, warning of risks

Yatai Pharm announced that the cumulative deviation of the stock price increase on October 31 and November 3, 2025, exceeded 20%, indicating abnormal fluctuations. The controlling shareholder, Fubon Group, intends to transfer 14.61% of its shares, and the actual controller will change to Qiu Zhongxun. The company also plans to conduct a private placement to Xinghao Holdings, which constitutes a related party transaction. Both matters carry uncertainties, and investors are reminded to pay attention to risks

A-share innovative drug concept stocks are active again, Sunshine Guojian Pharmaceutical rose over 10% to a new high, Yatai Pharm had two consecutive limit-ups, WECOME rose over 10%, and Baicheng Pharmaceutical, ALK, and Fushine followed suit

Yatai Pharm released its performance for the first three quarters, with a net profit attributable to the parent company of 97.195 million yuan, a year-on-year increase of 2909.49%

According to the Zhitong Finance APP, Yatai Pharm released its third-quarter report for 2025. In the first three quarters, the company achieved an operating income of 228 million yuan, a year-on-year decrease of 25.59%. The net profit attributable to shareholders of the listed company was 97.195 million yuan, a year-on-year increase of 2909.49%. The net loss attributable to shareholders of the listed company, after deducting non-recurring gains and losses, was 56.5853 million yuan

The actual controller of Yatai Pharm will change to Qiu Zhongxun, and trading will resume on October 14

Yatai Pharm announced that its controlling shareholder will change to Zhejiang Xinghao Holdings, and the actual controller will change to Qiu Zhongxun. The company plans to issue no more than 137 million shares to specific targets, with an issue price of 5.11 yuan per share, raising a total of no more than 700 million yuan, all of which will be used for new drug research and development. The stock will resume trading on October 14, 2025

Yatai Pharm: Signed a share transfer agreement, control rights are expected to change

Yatai Pharm announced that the company's controlling shareholder Fubon Group and its concerted party Hangu Investment have signed a Share Transfer Agreement with Xinghao Holdings and Xingchen Investment. Fubon Group and Hangu Investment plan to transfer 14.61% of the company's shares, totaling 109 million shares, through an agreement transfer. The transfer price is 8.26 yuan per share, with a total amount of 900 million yuan. If this transaction is ultimately implemented, the company's controlling shareholder will change from Fubon Group to Xinghao Holdings, and the actual controller of the company will change from the management team composed of Song Hanping, Fu Cai, and Hu Zhenghui to Qiu Zhongxun